1. Home
  2. MLYS vs MSEX Comparison

MLYS vs MSEX Comparison

Compare MLYS & MSEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • MSEX
  • Stock Information
  • Founded
  • MLYS 2019
  • MSEX 1897
  • Country
  • MLYS United States
  • MSEX United States
  • Employees
  • MLYS N/A
  • MSEX N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • MSEX Water Supply
  • Sector
  • MLYS Health Care
  • MSEX Utilities
  • Exchange
  • MLYS Nasdaq
  • MSEX Nasdaq
  • Market Cap
  • MLYS 1.0B
  • MSEX 933.6M
  • IPO Year
  • MLYS 2023
  • MSEX N/A
  • Fundamental
  • Price
  • MLYS $13.67
  • MSEX $52.39
  • Analyst Decision
  • MLYS Strong Buy
  • MSEX Buy
  • Analyst Count
  • MLYS 4
  • MSEX 4
  • Target Price
  • MLYS $27.00
  • MSEX $61.00
  • AVG Volume (30 Days)
  • MLYS 692.8K
  • MSEX 183.0K
  • Earning Date
  • MLYS 08-12-2025
  • MSEX 07-31-2025
  • Dividend Yield
  • MLYS N/A
  • MSEX 2.60%
  • EPS Growth
  • MLYS N/A
  • MSEX 17.05
  • EPS
  • MLYS N/A
  • MSEX 2.41
  • Revenue
  • MLYS N/A
  • MSEX $195,831,000.00
  • Revenue This Year
  • MLYS N/A
  • MSEX $6.54
  • Revenue Next Year
  • MLYS N/A
  • MSEX $7.47
  • P/E Ratio
  • MLYS N/A
  • MSEX $21.72
  • Revenue Growth
  • MLYS N/A
  • MSEX 11.91
  • 52 Week Low
  • MLYS $8.24
  • MSEX $48.18
  • 52 Week High
  • MLYS $18.38
  • MSEX $70.73
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 45.18
  • MSEX 40.21
  • Support Level
  • MLYS $13.41
  • MSEX $51.15
  • Resistance Level
  • MLYS $15.15
  • MSEX $52.91
  • Average True Range (ATR)
  • MLYS 0.73
  • MSEX 1.38
  • MACD
  • MLYS 0.01
  • MSEX -0.10
  • Stochastic Oscillator
  • MLYS 25.36
  • MSEX 38.90

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About MSEX Middlesex Water Company

Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.

Share on Social Networks: